drugset / Trial / NCT00344851

Exenatide and Metformin Therapy in Overweight Women With PCOS

NCT00344851

RandomizedParallel-groupOpen-labelTreatment

Summary

Current research has shown that the use of diabetes management practices aimed at reducing insulin resistance and hyperinsulinemia (such as weight reduction and the administration of oral antidiabetic drugs) in women with PCOS can not only improve glucose and lipid metabolism but can also reverse testosterone abnormalities and restore menstrual cycles. A new medicine called exenatide (Byetta) has been found to reduce body weight, as well as, improve abnormal glucose metabolism in diabetics. This randomized study will compare Exenatide (Byetta) to extended release metformin (Fortamet) to combination therapy (both Byetta and Fortamet) on menstrual cyclicity, hormone profiles and metabolic profiles over a 24-week period in women with PCOS.

Timeline

Start
2006-06
Primary completion
Completion
2007-06

Drugs

EvaluationDrugModalityDoseRoute
Subject Exenatide Peptide 10 ug
Subject Metformin Small molecule 1000 mg